MX2019003093A - Formas cristalinas. - Google Patents
Formas cristalinas.Info
- Publication number
- MX2019003093A MX2019003093A MX2019003093A MX2019003093A MX2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- crystal forms
- pharmaceutical compositions
- phosphonopropionyl
- pyrrolidine
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- GPOGKMPXBDGPJH-UHFFFAOYSA-N butan-2-yl acetate hydrochloride Chemical compound Cl.CCC(C)OC(C)=O GPOGKMPXBDGPJH-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención se relaciona a formas cristalinas de clorhidrato de éster butílico del ácido 4-((R)-2-{[6-((S)-3-metoxi-pirrolidina-1- iI)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-pip erazin-1-carboxílico, procesos para la preparación de las mismas, composiciones farmacéuticas que comprenden las formas cristalinas, composiciones farmacéuticas preparadas de las formas cristalinas y sus uso como un medicamento, especialmente como un antagonista del receptor P2Y12.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016072562 | 2016-09-22 | ||
| PCT/EP2017/073858 WO2018055016A1 (en) | 2016-09-22 | 2017-09-21 | Crystalline forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003093A true MX2019003093A (es) | 2019-07-18 |
| MX381590B MX381590B (es) | 2025-03-12 |
Family
ID=59923448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003093A MX381590B (es) | 2016-09-22 | 2017-09-21 | Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico. |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10730896B2 (es) |
| EP (2) | EP3981774A1 (es) |
| JP (1) | JP7097369B2 (es) |
| KR (1) | KR102552795B1 (es) |
| CN (1) | CN109715639B (es) |
| AU (1) | AU2017331930B2 (es) |
| CA (1) | CA3037794A1 (es) |
| CL (1) | CL2019000728A1 (es) |
| CY (1) | CY1125052T1 (es) |
| DK (1) | DK3515924T3 (es) |
| EA (1) | EA201990723A1 (es) |
| ES (1) | ES2908572T3 (es) |
| HR (1) | HRP20220234T1 (es) |
| HU (1) | HUE057772T2 (es) |
| IL (1) | IL265445B2 (es) |
| LT (1) | LT3515924T (es) |
| MA (1) | MA46266B1 (es) |
| MX (1) | MX381590B (es) |
| MY (1) | MY193080A (es) |
| PH (1) | PH12019500567B1 (es) |
| PL (1) | PL3515924T3 (es) |
| PT (1) | PT3515924T (es) |
| RS (1) | RS62946B1 (es) |
| SI (1) | SI3515924T1 (es) |
| TW (1) | TWI752086B (es) |
| UA (1) | UA124073C2 (es) |
| WO (1) | WO2018055016A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL265445B2 (en) | 2016-09-22 | 2024-05-01 | Idorsia Pharmaceuticals Ltd | crystalline forms |
| CN110381947A (zh) | 2017-03-15 | 2019-10-25 | 爱杜西亚药品有限公司 | P2y12受体拮抗剂的皮下施用 |
| IL299828A (en) | 2020-07-15 | 2023-03-01 | Idorsia Pharmaceuticals Ltd | An aqueous pharmaceutical preparation that includes a P2Y12 receptor antagonist |
| WO2023285342A2 (en) | 2021-07-13 | 2023-01-19 | Idorsia Pharmaceuticals Ltd | A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| AU5414000A (en) | 1999-06-14 | 2001-01-02 | Eli Lilly And Company | Compounds |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| BR0317222A (pt) | 2002-12-11 | 2005-11-01 | Schering Aktiengellschaft | Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas |
| PT1611144E (pt) | 2003-04-09 | 2010-11-12 | Wyeth Llc | Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda) |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| AU2006305538B2 (en) | 2005-10-21 | 2012-06-28 | Idorsia Pharmaceuticals Ltd | Piperazine derivatives as antimalarial agents |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| JP5309131B2 (ja) | 2007-04-23 | 2013-10-09 | サノフイ | Ｐ２ｙ１２アンタゴニストとしてのキノリン−カルボキサミド誘導体 |
| SI2225253T1 (sl) | 2007-11-29 | 2012-09-28 | Actelion Pharmaceuticals Ltd | Derivati fosfonske kisline in njihova uporaba kot antagonisti receptorja P2Y12 |
| JP5504171B2 (ja) | 2007-12-26 | 2014-05-28 | サノフイ | Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
| WO2009080227A2 (en) | 2007-12-26 | 2009-07-02 | Sanofi-Aventis | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| NZ596213A (en) | 2009-04-08 | 2013-05-31 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adenosine 5'-diphosphate (ADP) receptor antagonists |
| WO2010122504A1 (en) | 2009-04-22 | 2010-10-28 | Actelion Pharmaceuticals Ltd | Thiazole derivatives and their use as p2y12 receptor antagonists |
| IL265445B2 (en) | 2016-09-22 | 2024-05-01 | Idorsia Pharmaceuticals Ltd | crystalline forms |
| CN110381947A (zh) | 2017-03-15 | 2019-10-25 | 爱杜西亚药品有限公司 | P2y12受体拮抗剂的皮下施用 |
| IL299828A (en) | 2020-07-15 | 2023-03-01 | Idorsia Pharmaceuticals Ltd | An aqueous pharmaceutical preparation that includes a P2Y12 receptor antagonist |
-
2017
- 2017-09-21 IL IL265445A patent/IL265445B2/en unknown
- 2017-09-21 JP JP2019536696A patent/JP7097369B2/ja active Active
- 2017-09-21 WO PCT/EP2017/073858 patent/WO2018055016A1/en not_active Ceased
- 2017-09-21 TW TW106132387A patent/TWI752086B/zh active
- 2017-09-21 DK DK17771436.7T patent/DK3515924T3/da active
- 2017-09-21 KR KR1020197011330A patent/KR102552795B1/ko active Active
- 2017-09-21 CA CA3037794A patent/CA3037794A1/en active Pending
- 2017-09-21 MX MX2019003093A patent/MX381590B/es unknown
- 2017-09-21 PH PH1/2019/500567A patent/PH12019500567B1/en unknown
- 2017-09-21 HR HRP20220234TT patent/HRP20220234T1/hr unknown
- 2017-09-21 RS RS20220163A patent/RS62946B1/sr unknown
- 2017-09-21 US US16/335,973 patent/US10730896B2/en active Active
- 2017-09-21 EP EP21206477.8A patent/EP3981774A1/en not_active Withdrawn
- 2017-09-21 MY MYPI2019001474A patent/MY193080A/en unknown
- 2017-09-21 AU AU2017331930A patent/AU2017331930B2/en active Active
- 2017-09-21 EP EP17771436.7A patent/EP3515924B1/en active Active
- 2017-09-21 PT PT177714367T patent/PT3515924T/pt unknown
- 2017-09-21 PL PL17771436T patent/PL3515924T3/pl unknown
- 2017-09-21 ES ES17771436T patent/ES2908572T3/es active Active
- 2017-09-21 CN CN201780057793.2A patent/CN109715639B/zh active Active
- 2017-09-21 SI SI201731102T patent/SI3515924T1/sl unknown
- 2017-09-21 UA UAA201903751A patent/UA124073C2/uk unknown
- 2017-09-21 MA MA46266A patent/MA46266B1/fr unknown
- 2017-09-21 EA EA201990723A patent/EA201990723A1/ru unknown
- 2017-09-21 HU HUE17771436A patent/HUE057772T2/hu unknown
- 2017-09-21 LT LTEPPCT/EP2017/073858T patent/LT3515924T/lt unknown
-
2019
- 2019-03-21 CL CL2019000728A patent/CL2019000728A1/es unknown
-
2020
- 2020-07-24 US US16/938,730 patent/US11365209B2/en active Active
-
2022
- 2022-03-09 CY CY20221100195T patent/CY1125052T1/el unknown
- 2022-05-10 US US17/741,427 patent/US12227532B2/en active Active
-
2025
- 2025-01-17 US US19/028,423 patent/US20250163086A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002650A1 (es) | Compuestos novedosos | |
| ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| ECSP17078433A (es) | Composiciones de ácido obeticólico y métodos de uso | |
| BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| MX373318B (es) | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer. | |
| BR102015032361A8 (pt) | Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura | |
| ECSP17030878A (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| ECSP16059106A (es) | Composiciones de liberación retardada de linaclotida | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| CR20160374A (es) | Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina | |
| MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
| MX2017002913A (es) | Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida. | |
| MX2017011330A (es) | Proceso quimico para preparar derivados de pirimidina y sus intermediarios. | |
| MX2019003093A (es) | Formas cristalinas. | |
| ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
| CL2018000665A1 (es) | Formas cristalinas | |
| MX2018003564A (es) | 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer. | |
| BR112017009852A2 (pt) | composto, composição, e, usos de um composto |